Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: A 24-month follow-up study

L. Niccoli, C. Nannini, M. Benucci, D. Chindamo, E. Cassaŕ, C. Salvarani, L. Cimino, G. Gini, I. Lenzetti, Fabrizio Cantini

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Objectives. To evaluate the long-term efficacy and safety of infliximab in patients with Behçet's disease (BD) and refractory bilateral posterior uveitis, and to assess the proportion of relapse-free subjects through months 12 and 24. Methods. Open-label, multicentre, 24-month, prospective, follow up study on 12 consecutive patients with BD and refractory posterior uveitis who had failed at least one immunosuppressive drug. At baseline patients received prednisolone 1 mg/Kg/day with rapid tapering and nine infliximab infusions (5 mg/kg) over a 12-month period. Non-responders after the third infusion withdrew from the study. Patients were evaluated for ocular inflammation degree, visual acuity (VA), number of ocular attacks and incidence of adverse events (AEs). Results. At 12-month visit, 9/12 (75%) patients achieved a complete remission with no relapse during the treatment period. All had a dramatic improvement of ocular inflammation after the first infusion, six were in complete remission after three infusions, and three after four. All these patients suspended corticosteroids at week 22. At 24-month visit, seven out of nine (78%) were still in remission. Mean VA improved from 0.2 ± 0.6 to 0.5 ± 0.2 (P <0.001), and ocular attacks dropped from 40 in the year before therapy to 5 after infliximab cessation (P<0.001). One patient had a partial remission with two relapses during treatment, and 2/12 (17%) patients showed no improvement. Infliximab was well tolerated with no serious AEs. Conclusions. Infliximab is rapidly effective and safe in a high proportion BD patients with refractory posterior uveitis, and may be helpful to prevent recurrences.

Original languageEnglish
Pages (from-to)1161-1164
Number of pages4
JournalRheumatology
Volume46
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Posterior Uveitis
Recurrence
Visual Acuity
Inflammation
Infliximab
Immunosuppressive Agents
Prednisolone
Adrenal Cortex Hormones
Therapeutics

Keywords

  • Anti-TNF-α drugs
  • Behçet's disease
  • Infliximab
  • Retinal vasculitis
  • Uveitis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease : A 24-month follow-up study. / Niccoli, L.; Nannini, C.; Benucci, M.; Chindamo, D.; Cassaŕ, E.; Salvarani, C.; Cimino, L.; Gini, G.; Lenzetti, I.; Cantini, Fabrizio.

In: Rheumatology, Vol. 46, No. 7, 07.2007, p. 1161-1164.

Research output: Contribution to journalArticle

Niccoli, L, Nannini, C, Benucci, M, Chindamo, D, Cassaŕ, E, Salvarani, C, Cimino, L, Gini, G, Lenzetti, I & Cantini, F 2007, 'Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: A 24-month follow-up study', Rheumatology, vol. 46, no. 7, pp. 1161-1164. https://doi.org/10.1093/rheumatology/kem101
Niccoli, L. ; Nannini, C. ; Benucci, M. ; Chindamo, D. ; Cassaŕ, E. ; Salvarani, C. ; Cimino, L. ; Gini, G. ; Lenzetti, I. ; Cantini, Fabrizio. / Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease : A 24-month follow-up study. In: Rheumatology. 2007 ; Vol. 46, No. 7. pp. 1161-1164.
@article{77dc81c059e847e7a594980245072605,
title = "Long-term efficacy of infliximab in refractory posterior uveitis of Beh{\cc}et's disease: A 24-month follow-up study",
abstract = "Objectives. To evaluate the long-term efficacy and safety of infliximab in patients with Beh{\cc}et's disease (BD) and refractory bilateral posterior uveitis, and to assess the proportion of relapse-free subjects through months 12 and 24. Methods. Open-label, multicentre, 24-month, prospective, follow up study on 12 consecutive patients with BD and refractory posterior uveitis who had failed at least one immunosuppressive drug. At baseline patients received prednisolone 1 mg/Kg/day with rapid tapering and nine infliximab infusions (5 mg/kg) over a 12-month period. Non-responders after the third infusion withdrew from the study. Patients were evaluated for ocular inflammation degree, visual acuity (VA), number of ocular attacks and incidence of adverse events (AEs). Results. At 12-month visit, 9/12 (75{\%}) patients achieved a complete remission with no relapse during the treatment period. All had a dramatic improvement of ocular inflammation after the first infusion, six were in complete remission after three infusions, and three after four. All these patients suspended corticosteroids at week 22. At 24-month visit, seven out of nine (78{\%}) were still in remission. Mean VA improved from 0.2 ± 0.6 to 0.5 ± 0.2 (P <0.001), and ocular attacks dropped from 40 in the year before therapy to 5 after infliximab cessation (P<0.001). One patient had a partial remission with two relapses during treatment, and 2/12 (17{\%}) patients showed no improvement. Infliximab was well tolerated with no serious AEs. Conclusions. Infliximab is rapidly effective and safe in a high proportion BD patients with refractory posterior uveitis, and may be helpful to prevent recurrences.",
keywords = "Anti-TNF-α drugs, Beh{\cc}et's disease, Infliximab, Retinal vasculitis, Uveitis",
author = "L. Niccoli and C. Nannini and M. Benucci and D. Chindamo and E. Cassaŕ and C. Salvarani and L. Cimino and G. Gini and I. Lenzetti and Fabrizio Cantini",
year = "2007",
month = "7",
doi = "10.1093/rheumatology/kem101",
language = "English",
volume = "46",
pages = "1161--1164",
journal = "Rheumatology",
issn = "1462-0324",
publisher = ". Published by Oxford University Press on behalf of the British Society for Rheumatology",
number = "7",

}

TY - JOUR

T1 - Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease

T2 - A 24-month follow-up study

AU - Niccoli, L.

AU - Nannini, C.

AU - Benucci, M.

AU - Chindamo, D.

AU - Cassaŕ, E.

AU - Salvarani, C.

AU - Cimino, L.

AU - Gini, G.

AU - Lenzetti, I.

AU - Cantini, Fabrizio

PY - 2007/7

Y1 - 2007/7

N2 - Objectives. To evaluate the long-term efficacy and safety of infliximab in patients with Behçet's disease (BD) and refractory bilateral posterior uveitis, and to assess the proportion of relapse-free subjects through months 12 and 24. Methods. Open-label, multicentre, 24-month, prospective, follow up study on 12 consecutive patients with BD and refractory posterior uveitis who had failed at least one immunosuppressive drug. At baseline patients received prednisolone 1 mg/Kg/day with rapid tapering and nine infliximab infusions (5 mg/kg) over a 12-month period. Non-responders after the third infusion withdrew from the study. Patients were evaluated for ocular inflammation degree, visual acuity (VA), number of ocular attacks and incidence of adverse events (AEs). Results. At 12-month visit, 9/12 (75%) patients achieved a complete remission with no relapse during the treatment period. All had a dramatic improvement of ocular inflammation after the first infusion, six were in complete remission after three infusions, and three after four. All these patients suspended corticosteroids at week 22. At 24-month visit, seven out of nine (78%) were still in remission. Mean VA improved from 0.2 ± 0.6 to 0.5 ± 0.2 (P <0.001), and ocular attacks dropped from 40 in the year before therapy to 5 after infliximab cessation (P<0.001). One patient had a partial remission with two relapses during treatment, and 2/12 (17%) patients showed no improvement. Infliximab was well tolerated with no serious AEs. Conclusions. Infliximab is rapidly effective and safe in a high proportion BD patients with refractory posterior uveitis, and may be helpful to prevent recurrences.

AB - Objectives. To evaluate the long-term efficacy and safety of infliximab in patients with Behçet's disease (BD) and refractory bilateral posterior uveitis, and to assess the proportion of relapse-free subjects through months 12 and 24. Methods. Open-label, multicentre, 24-month, prospective, follow up study on 12 consecutive patients with BD and refractory posterior uveitis who had failed at least one immunosuppressive drug. At baseline patients received prednisolone 1 mg/Kg/day with rapid tapering and nine infliximab infusions (5 mg/kg) over a 12-month period. Non-responders after the third infusion withdrew from the study. Patients were evaluated for ocular inflammation degree, visual acuity (VA), number of ocular attacks and incidence of adverse events (AEs). Results. At 12-month visit, 9/12 (75%) patients achieved a complete remission with no relapse during the treatment period. All had a dramatic improvement of ocular inflammation after the first infusion, six were in complete remission after three infusions, and three after four. All these patients suspended corticosteroids at week 22. At 24-month visit, seven out of nine (78%) were still in remission. Mean VA improved from 0.2 ± 0.6 to 0.5 ± 0.2 (P <0.001), and ocular attacks dropped from 40 in the year before therapy to 5 after infliximab cessation (P<0.001). One patient had a partial remission with two relapses during treatment, and 2/12 (17%) patients showed no improvement. Infliximab was well tolerated with no serious AEs. Conclusions. Infliximab is rapidly effective and safe in a high proportion BD patients with refractory posterior uveitis, and may be helpful to prevent recurrences.

KW - Anti-TNF-α drugs

KW - Behçet's disease

KW - Infliximab

KW - Retinal vasculitis

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=34447331009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447331009&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kem101

DO - 10.1093/rheumatology/kem101

M3 - Article

C2 - 17478466

AN - SCOPUS:34447331009

VL - 46

SP - 1161

EP - 1164

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 7

ER -